多西他赛联合洛铂治疗转移性乳腺癌的临床效果分析

Clinical effect of docetaxel combined with lobaplafin in the treatment of metastatic breast cancer

目的 分析多西他赛联合洛铂治疗转移性乳腺癌的临床效果。方法 选择转移型乳腺癌患者46例为研究对象，患者均给予多西他赛联合洛铂治疗，观察临床治疗效果。结果 经4个周期的治疗，46例患者中，完全缓解（CR）4例，部分缓解（PR）25例，临床治疗有效率为63.0%（29/46）。对患者进行为期12个月的随访发现，患者的无进展生存时间平均为（8.1±0.6）个月；2例患者因肿瘤进展而死亡。不良反应主要为粒细胞减少、血小板减少、乏力、胃肠道反应、关节肌肉酸痛、黏膜炎、腹泻以及周围性水肿，主要为Ⅰ～Ⅱ度。结论 多西他赛联合洛铂对转移性乳腺癌患者具有比较理想的近期临床治疗效果，不良反应轻。

Objective To analyze the efficacy and safety of combination of docetaxel and lobaplatin in the treatment of metastatic breast cancer（MBC）.Methods The clinical data of 46 patients with MBC who had been administered docetaxel and lobaplatin were retrospectively reviewed.Results All 46 patients were treated for 4 cycles,4 cases achieved complete remission（CR）,25 cases achieved partial remission（PR）,the effective rate was 63.0%（29/46）.The patients were followed up for 12 monthpatients,the progression-free survival time was（8.1±0.6）months,2 patients died due to tumor progression.The adverse reactions were mainly granulocyte,thrombocytopenia,anemic,gastrointestinal reaction,articular muscle soreness,mucosa,diarrhea and peripheral edema,mainly I^II degree.Conclusion Docetaxel combined with lobaplatin is well-tolerated and safe for MBC patients,and has less adverse reactions.